Present-day is developing in many fields. Many pathological processes are better understood, including carcinogenesis. Consequently, the failure of pharmacotherapy aimed at cancerous diseases is becoming explainable. At the same time, new anticancer drugs continue to be introduced. Anthracycline antibiotics are a well-known and widely used group of anticancer drugs. However, in addition to their efficiency they demonstrate severe side effects compounded by the appearance of resistant cells. Therefore, the search for new anthracycline derivatives with improved pharmacodynamic properties and fewer adverse effects is in progress, delivering promising results.